CompletedPhase 2NCT03836001
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa
Studying Inherited epidermolysis bullosa
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Stanford University
- Principal Investigator
- Albert S Chiou, MD/MBA, MDStanford University
- Intervention
- Serlopitant Tablet(drug)
- Enrollment
- 28 target
- Eligibility
- 13 years · All sexes
- Timeline
- 2019 – 2022
Study locations (1)
- Stanford University, Redwood City, California, United States
Collaborators
Epidermolysis Bullosa Research Partnership · Vyne Therapeutics Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03836001 on ClinicalTrials.govOther trials for Inherited epidermolysis bullosa
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT05838092Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)RHEACELL GmbH & Co. KG
- ACTIVE NOT RECRUITINGPHASE3NCT05464381Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)RHEACELL GmbH & Co. KG
- ACTIVE NOT RECRUITINGNANCT05248503Impact of Complex Care Training of Hereditary Epidermolysis Bullosa on Caregiver Burden (FIREB)Assistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT05954416FARD (RaDiCo Cohort) (RaDiCo-FARD)Institut National de la Santé Et de la Recherche Médicale, France